Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

342 results about "Gene copy" patented technology

Transgenic microbial polyhydroxyalkanoate producers

Transgenic microbial strains are provided which contain the genes required for PHA formation integrated on the chromosome. The strains are advantageous in PHA production processes, because (1) no plasmids need to be maintained, generally obviating the required use of antibiotics or other stabilizing pressures, and (2) no plasmid loss occurs, thereby stabilizing the number of gene copies per cell throughout the fermentation process, resulting in homogeneous PHA product formation throughout the production process. Genes are integrated using standard techniques, preferably transposon mutagenesis. In a preferred embodiment wherein mutiple genes are incorporated, these are incorporated as an operon. Sequences are used to stabilize mRNA, to induce expression as a function of culture conditions (such as phosphate concentration), temperature, and stress, and to aid in selection, through the incorporation of selection markers such as markers conferring antibiotic resistance.
Owner:CJ CHEILJEDANG CORP

Method for predicating homologous recombination deficiency mechanism and method for predicating response of patients to cancer therapy

InactiveCN107287285AInnovativeOvercoming the pitfalls of inaccurate forecastsMicrobiological testing/measurementSequence analysisAbnormal tissue growthPolymerase L
The invention discloses a method for predicating a homologous recombination deficiency (HRD) mechanism and a method for predicating response of patients to cancer therapy and relates to the field of biological information predication. The method comprises the step of judging whether a tumor sample has homologous recombination deficiency or not according to one or more comprehensive values in a large-segment INDEL (Insertion/Deletion) fraction, a copy number variation fraction and a tumor mutation load fraction, wherein the comprehensive values can also comprise a loss of heterozygosity variation fraction. By adopting the method disclosed by the invention, predication of a chromosome large-segment structure, a chromosome gene type number, a chromosome gene copy number, a chromosome variation interval and abnormal loss of heterozygosity and chromosome telomeric imbalance is realized, so that an evaluation range is more complete and HRD can be accurately predicated; the comprehensive values also can be used for determining whether the patients have response to a therapeutic regimen containing one or more of a PARP (Poly Adenosine Diphosphate Ribose Polymerase) inhibitor, an DNA (Deoxyribonucleic Acid) injury inhibitor, a topoisomerase II/II+inhibitor, a topoisomerase I inhibitor and radiotherapy; the method is simple and has wide general applicability.
Owner:SHANGHAI ORIGIMED CO LTD

Genetic amplification of IQGAP1 in cancer

ActiveUS9157123B2Diminish invasivenessReduce spreadOrganic active ingredientsSugar derivativesCell invasionFollicular thyroid cancer
We examined IQGAP1 copy gain and its relationship with clinicopathologic outcomes of thyroid cancer and investigated its role in cell invasion and molecules involved in the process. We found IQGAP1 copy number (CN) gain ?3 in 1 of 30 (3%) of benign thyroid tumor, 24 of 74 (32%) follicular variant papillary thyroid cancer (FVPTC), 44 of 107 (41%) follicular thyroid cancer (FTC), 8 of 16 (50%) tall cell papillary thyroid cancer (PTC), and 27 of 41 (66%) anaplastic thyroid cancer, in increasing order of invasiveness of these tumors. A similar tumor distribution trend of CN ?4 was also seen. IQGAP1 copy gain was positively correlated with IQGAP1 protein expression. It was significantly associated with extrathyroidal and vascular invasion of FVPTC and FTC and, remarkably, a 50%-60% rate of multifocality and recurrence of BRAF mutation-positive PTC (P=0.01 and 0.02, respectively). The siRNA knock-down of IQGAP1 dramatically inhibited thyroid cancer cell invasion and colony formation. Co-immunoprecipitation assay showed direct interaction of IQGAP1 with E-cadherin, a known invasion-suppressing molecule, which was upregulated when IQGAP1 was knocked down. IQGAP1, through genetic copy gain, plays an important role in the invasiveness of thyroid cancer and represents a useful prognostic marker and therapeutic target for this and other cancers.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE

Multi-copy high expressed recombined plectasin by pichia pastoris

ActiveCN102409003AIncrease expression abundanceFungiAntibody mimetics/scaffoldsPichia pastorisPlectasin
The invention discloses a preparation method of multi-copy high expressed recombined plectasin by pichia pastoris. The method comprises the following steps: a plectasin expressing gene sequence is designed according to preference performance to codon translated by pichia pastoris; the optimized plectasin gene is fused on an alpha-factor signal peptide C terminus of an expression vector pPICZalphaA to construct a single-copy expression vector, the vector comprises a plectasin expression cassette containing a start signal element alcohol oxygen dehydrogenase strong promoter (AOX), alpha-factor signal peptide gene and a plectasin gene fused in C terminus, a stop signal element AOX (TT) and the like. A complementation principle of restriction endonuclease Bg1II and BamHI cohesive end is used to obtain plectasin gene-containing recombinant plasmid of different copy cascade expression cassettes, pichia pastoris is electrotransformed and secreted and expressed plectasin with high efficiency under the methanol induction. The expression level and plectasin gene copy number exist a linear relation. The constructed multi-copy high expressed yeast cells can be used for raising the output and reducing the cost, and is adapted to large scale production of plectasin.
Owner:FEED RESEARCH INSTITUTE CHINESE ACADEMY OF AGRICULTURAL SCIENCES

Anti-EGFR antibody therapy based on an increased copy number of the EGFR gene in tumor tissues

InactiveUS20090269344A1Survival predictionHigh gene copy numberMicrobiological testing/measurementAntibody ingredientsAnti-EGFR AntibodyFhit gene
The invention relates to an indidualized and personalized diagnosis and therapy of cancer based on specific molecular alterations which occur in specific tumor tissue of specific tumor patient populations. The therapy and diagnostic is based on the findings that proliferation and tumor growth of specific EGFR bearing tumor tissue expressing an amplified EGFR gene copy number may be abolished by anti-EGFR antibodies, while other individual molecular alterations such as mutations occurring in tumor tissues are unaffected by the same anti-EGFR antibody treatment.
Owner:MERCK PATENT GMBH

Methods for determining the specificity and sensitivity of oligonucleo tides for hybridization

The present invention provides materials and methods which may be used to evaluate one or more different probes and select probes that are optimized for sensitivity and specificity for a particular target. In particularly preferred embodiments, the methods and compositions of the invention can be used to evaluate polynucleotide probes having different nucleotide sequences. The methods and compositions thereby allow a user to select a polynucleotide probe, e.g., having a particular nucleotide sequence, that is optimized for sensitivity and / or for specificity for a particular target polynucleotide molecule. In particularly preferred embodiments, the methods and compositions can be used to evaluate a plurality of probes simultaneously, such as on a microarray.Probes evaluated according to the methods of the invention can be selected for and used to detect a variety molecules, including a variety of polynucleotides, such as genomic polynucleotides (e.g., genomic DNA) and genomic transcripts (e.g., mRNAs or cDNA sequences derived from there) as well as gene copy numbers of specific transcripts, single nucleotide polymorphisms, etc.
Owner:MERCK SHARP & DOHME CORP

Construction of saccharomyces cerevisiae engineering bacteria generating beta-phenethyl alcohol, strain and application thereof

InactiveCN103409332ASingle configurationChiral singleFungiMicroorganism based processesAlcohol ethylPhenethyl alcohol
The invention relates to construction of saccharomyces cerevisiae engineering bacteria generating beta-phenethyl alcohol, a strain and application thereof, and belongs to the technical field of bioengineering and production of food spices. The prepared beta-phenethyl alcohol spice is a natural spice and can be used for preparing a plurality of food essences, and therefore, the beta-phenethyl alcohol can be widely applied to industries such as food, medicine and daily use chemicals. Engineering bacterial for coupling overexpression of an aminotransferase gene (ARO8) and decarboxylase gene (ARO10) in the anabolic way of beta-phenethyl are designed and constructed with saccharomycescerevisiae S288 as an original strain; gene copy and expression of the two key enzymes in the main synthetic way are enhanced; the bred engineering bacteria (transformants) are passaged a plurality of times and stable in inheritance; the metabolic flux and the yield of beta-phenethyl are obviously improved. With L-phenylalanine as a major raw material, the engineering bacteria are used for fermenting and converting the raw material into the beta-phenethyl alcohol spice which is single in configuration and chirality and high in fragrance quality, and therefore, a new idea and technical support are provided for preparation of the natural beta-phenethyl alcohol spice.
Owner:BEIJING TECHNOLOGY AND BUSINESS UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products